María del Mar Mañú-Pereira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
María del Mar Mañú-Pereira has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Beatriz Galatas
Affiliations Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique, ISGlobal, Hospital Clínic—Universitat de Barcelona, Barcelona, Spain
1 shared publication - Clara Menéndez
ISGlobal
1 shared publication Esther Llaudet-Planas
1 shared publication- Eusébio Macete
Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique
1 shared publication - Francisco Saute
Centro de Investigação em Saude de Manhiça, Manhiça, Mozambique
1 shared publication - Gloria Matambisso
Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique
1 shared publication
Latest Publications
- Open Access
- 19 January 2017
- Published by Springer Nature in Malaria Journal
- Vol. 16 (1) , 1-8
Heterogeneity of G6PD deficiency prevalence in Mozambique: a school-based cross-sectional survey in three different regions
Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked hereditary enzymatic abnormality that affects more than 400 million people worldwide. Most deficient individuals do not manifest any symptoms; however, several precipitant agents—such as fava intake, infections, or several drugs—may trigger acute haemolytic anaemia. Countries should be informed of the prevalence of this enzymatic anomaly within their borders, in order to make safe and appropriate national decisions regarding the use of potentially unsafe drugs for G6PD deficient individuals. Methods: A school-based cross-sectional survey was conducted in three districts in Mozambique, namely Manhiça, located in the south; Mocuba in the centre; and Pemba in the northern tip of the country. G6PD deficiency was evaluated using the CareStart™ diagnostic test, and enzyme activity levels were measured through fluorescence spectrophotometry in deficient individuals. Chi squared and ANOVA tests were used to assess prevalence and mean enzyme activity differences, and logistic regression was used to identify risk factors associated to the deficiency. Results: G6PD deficiency prevalence estimates were lowest in the northern city of Pemba (8.3%) and among Emakhuwas and Shimakondes, and higher in the centre and southern regions of the country (16.8 and 14.6%, respectively), particularly among Elomwes and Xichanganas. G6PD deficiency was significantly more prevalent among male students than females (OR = 1.4, 95% CI 1.0–1.8, p = 0.02), although enzyme activity levels were not different among deficient individuals from either gender group. Finally, median deficiency levels were found to be more severe among the deficient students from the north (0.7 U/gHg [0.2–0.7] p < 0.001) and south (0.7 U/gHg [0.5–2.5]), compared to those from the centre (1.4 U/gHg [0.6–2.1]). Conclusion: These findings suggest that Mozambique, as a historically high malaria-endemic country has considerable levels of G6PD deficiency, that vary significantly across the country. This should be considered when planning national strategies for the use of licensed drugs that may be associated to haemolysis among G6PD individuals, or prior to the performance of future trials using primaquine and other 8-aminoquinolines derivatives. Registration Number CISM local ethics committee (CIBS-25/013, 4th of December 2013), and the National Ethics Committee of Mozambique (IRB00002657, 28th of February 2014).
- 19 January 2017
- Published by Springer Nature in Malaria Journal
- Vol. 16 (1) , 1-8
Open AccessHeterogeneity of G6PD deficiency prevalence in Mozambique: a school-based cross-sectional survey in three different regions
Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked hereditary enzymatic abnormality that affects more than 400 million people worldwide. Most deficient individuals do not manifest any symptoms; however, several precipitant agents—such as fava intake, infections, or several drugs—may trigger acute haemolytic anaemia. Countries should be informed of the prevalence of this enzymatic anomaly within their borders, in order to make safe and appropriate national decisions regarding the use of potentially unsafe drugs for G6PD deficient individuals. Methods: A school-based cross-sectional survey was conducted in three districts in Mozambique, namely Manhiça, located in the south; Mocuba in the centre; and Pemba in the northern tip of the country. G6PD deficiency was evaluated using the CareStart™ diagnostic test, and enzyme activity levels were measured through fluorescence spectrophotometry in deficient individuals. Chi squared and ANOVA tests were used to assess prevalence and mean enzyme activity differences, and logistic regression was used to identify risk factors associated to the deficiency. Results: G6PD deficiency prevalence estimates were lowest in the northern city of Pemba (8.3%) and among Emakhuwas and Shimakondes, and higher in the centre and southern regions of the country (16.8 and 14.6%, respectively), particularly among Elomwes and Xichanganas. G6PD deficiency was significantly more prevalent among male students than females (OR = 1.4, 95% CI 1.0–1.8, p = 0.02), although enzyme activity levels were not different among deficient individuals from either gender group. Finally, median deficiency levels were found to be more severe among the deficient students from the north (0.7 U/gHg [0.2–0.7] p < 0.001) and south (0.7 U/gHg [0.5–2.5]), compared to those from the centre (1.4 U/gHg [0.6–2.1]). Conclusion: These findings suggest that Mozambique, as a historically high malaria-endemic country has considerable levels of G6PD deficiency, that vary significantly across the country. This should be considered when planning national strategies for the use of licensed drugs that may be associated to haemolysis among G6PD individuals, or prior to the performance of future trials using primaquine and other 8-aminoquinolines derivatives. Registration Number CISM local ethics committee (CIBS-25/013, 4th of December 2013), and the National Ethics Committee of Mozambique (IRB00002657, 28th of February 2014).
- 1 January 2017
- Published by Elsevier in Medicina Clínica (English Edition)
- Vol. 148 (1) , 23-27
Red cell pyruvate kinase deficiency in Spain: A study of 15 cases
- 1 January 2017
- Published by Elsevier in Medicina Clínica (English Edition)
- Vol. 148 (1) , 23-27
Red cell pyruvate kinase deficiency in Spain: A study of 15 cases
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 4, 393
First description of phosphofructokinase deficiency in spain: identification of a novel homozygous missense mutation in the PFKM gene
Phosphofructokinase deficiency is a very rare autosomal recessive disorder, which belongs to group of rare inborn errors of metabolism called glycogen storage disease. Here we report on a new mutation in the phosphofructokinase (PFK) gene PFKM identified in a 65-year-old woman who suffered from lifelong intermittent muscle weakness and painful spasms of random occurrence, episodic dark urines, and slight haemolytic anaemia. After ruling out the most common causes of chronic haemolytic anaemia, the study of a panel of 24 enzyme activities showed a markedly decreased PFK activity in red blood cells from the patient. DNA sequence analysis of the PFKM gene subsequently revealed a novel homozygous mutation: c.926A>G; p.Asp309Gly. This mutation is predicted to severely affect enzyme catalysis thereby accounting for the observed enzyme deficiency. This case represents a prime example of classical PFK deficiency and is the first reported case of this very rare red blood cell disorder in Spain.
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 4, 393
Open AccessFirst description of phosphofructokinase deficiency in spain: identification of a novel homozygous missense mutation in the PFKM gene
Phosphofructokinase deficiency is a very rare autosomal recessive disorder, which belongs to group of rare inborn errors of metabolism called glycogen storage disease. Here we report on a new mutation in the phosphofructokinase (PFK) gene PFKM identified in a 65-year-old woman who suffered from lifelong intermittent muscle weakness and painful spasms of random occurrence, episodic dark urines, and slight haemolytic anaemia. After ruling out the most common causes of chronic haemolytic anaemia, the study of a panel of 24 enzyme activities showed a markedly decreased PFK activity in red blood cells from the patient. DNA sequence analysis of the PFKM gene subsequently revealed a novel homozygous mutation: c.926A>G; p.Asp309Gly. This mutation is predicted to severely affect enzyme catalysis thereby accounting for the observed enzyme deficiency. This case represents a prime example of classical PFK deficiency and is the first reported case of this very rare red blood cell disorder in Spain.